This website is intended for healthcare professionals only. The posters accessed through this page may discuss and/or present information on investigational uses of nintedanib for which effectiveness and safety have not been established. Nintedanib is indicated for (i) treatment for idiopathic pulmonary fibrosis; (ii) treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype; and (iii) slowing the rate of decline of pulmonary function in patients with systemic sclerosis-associated interstitial lung disease.
